292 related articles for article (PubMed ID: 29558894)
1. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries.
Wright CM; Boudarène L; Ha NT; Wu O; Hawkins N
BMC Public Health; 2018 Mar; 18(1):373. PubMed ID: 29558894
[TBL] [Abstract][Full Text] [Related]
2. Strategies for the prevention of perinatal hepatitis B transmission in a marginalized population on the Thailand-Myanmar border: a cost-effectiveness analysis.
Devine A; Harvey R; Min AM; Gilder MET; Paw MK; Kang J; Watts I; Hanboonkunupakarn B; Nosten F; McGready R
BMC Infect Dis; 2017 Aug; 17(1):552. PubMed ID: 28793866
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
[TBL] [Abstract][Full Text] [Related]
5. An economic analysis of premarriage prevention of hepatitis B transmission in Iran.
Adibi P; Rezailashkajani M; Roshandel D; Behrouz N; Ansari S; Somi MH; Shahraz S; Zali MR
BMC Infect Dis; 2004 Sep; 4():31. PubMed ID: 15347430
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
Vimolket T; Poovorawan Y
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review.
Ozawa S; Mirelman A; Stack ML; Walker DG; Levine OS
Vaccine; 2012 Dec; 31(1):96-108. PubMed ID: 23142307
[TBL] [Abstract][Full Text] [Related]
8. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis.
Nguyen LBL; Lemoine M; Ndow G; Ward ZJ; Hallet TB; D'Alessandro U; Thursz M; Nayagam S; Shimakawa Y
Lancet Glob Health; 2024 Jan; 12(1):e66-e78. PubMed ID: 38097300
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis.
Rossi C; Schwartzman K; Oxlade O; Klein MB; Greenaway C
PLoS One; 2013; 8(10):e78548. PubMed ID: 24205255
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013].
Zhang SX; Sun PP; Xia Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719
[No Abstract] [Full Text] [Related]
11. The Effectiveness and Cost-Effectiveness of Screening for and Vaccination Against Hepatitis B Virus among Migrants in the EU/EEA: A Systematic Review.
Myran DT; Morton R; Biggs BA; Veldhuijzen I; Castelli F; Tran A; Staub LP; Agbata E; Rahman P; Pareek M; Noori T; Pottie K
Int J Environ Res Public Health; 2018 Sep; 15(9):. PubMed ID: 30200406
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
[TBL] [Abstract][Full Text] [Related]
13. Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies.
Leech AA; Kim DD; Cohen JT; Neumann PJ
Value Health; 2018 Jul; 21(7):759-761. PubMed ID: 30005746
[TBL] [Abstract][Full Text] [Related]
14. Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022.
Gharpure R; Chard AN; Cabrera Escobar M; Zhou W; Valleau MM; Yau TS; Bresee JS; Azziz-Baumgartner E; Pallas SW; Lafond KE
PLoS Med; 2024 Jan; 21(1):e1004333. PubMed ID: 38181066
[TBL] [Abstract][Full Text] [Related]
15. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
Custer B; Janssen MP; Hubben G; Vermeulen M; van Hulst M
Vox Sang; 2017 Aug; 112(6):526-534. PubMed ID: 28597489
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries.
Nayagam S; Sicuri E; Lemoine M; Easterbrook P; Conteh L; Hallett TB; Thursz M
BMC Infect Dis; 2017 Nov; 17(Suppl 1):692. PubMed ID: 29143675
[TBL] [Abstract][Full Text] [Related]
17. Cost-benefit comparison of two proposed overseas programs for reducing chronic Hepatitis B infection among refugees: is screening essential?
Jazwa A; Coleman MS; Gazmararian J; Wingate LT; Maskery B; Mitchell T; Weinberg M
Vaccine; 2015 Mar; 33(11):1393-9. PubMed ID: 25595868
[TBL] [Abstract][Full Text] [Related]
18. Interventions for the prevention of cardiovascular diseases: a protocol for a systematic review of economic evaluations in low-income and middle-income countries.
Aminde LN; Veerman L
BMJ Open; 2016 Dec; 6(12):e013668. PubMed ID: 28003298
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.
Fesenfeld M; Hutubessy R; Jit M
Vaccine; 2013 Aug; 31(37):3786-804. PubMed ID: 23830973
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
